Study of the Combination of CM082 With Everolimus in Patients With mRCC

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma * Progressed on at least one standard therapy * Measurable disease per Recist1.1 * Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1 * Life expectancy of at least 12 weeks * No abnormal bone marrow function * Adequate heart, lung, liver, kidney organ system functions, and meet the following requirements: * Total bilirubin ≤1.5 times the upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤5x the upper limit of normal with liver involvement. * Creatinine ≤ 1.5 x ULN * Urine protein \<1+ * QTcF \< 450 ms * LVEF ≥ 50% * At least 4 weeks after receiving cancer therapy (i.e., chemotherapy, radiation therapy, biologic therapy, hormonal therapy); 3 months after surgery and recovered * Willingness and ability to comply with trial and follow-up procedures * Ability to understand the nature of this trial and give written informed consent Exclusion Criteria: * Currently receiving anti-cancer treatment * Other tumors in addition to renal cell carcinoma * Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks * Concomitant use of drugs with a risk of causing prolonged corrected QT interval and/or Torsades de Pointes * Patients with a history of intolerance to, or significant toxicity with VEGFR tyrosine kinase inhibitor(s) (TKI) or everolimus * Females who are pregnant or breastfeeding * Those in reproductive ages who refuse to use contraception * Those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol * Patients with known central nervous system (CNS) metastases * Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM082 or everolimus * Patients with known severe lung disorders such as asthma, chronic obstructive pulmonary disease (COPD) * Patients who are HIV positive * Drug or alcohol abuser